PM Images LAVA Therapeutics (NASDAQ:LVTX) announced Tuesday that Pfizer (PFE) had reached a key milestone in its clinical program for cancer candidate PF-08046052, leading to a $7M payment to the Dutch biotech as the first milestone payment in a collaboration between the two firms. “We are very pleased with the initiation of clinical development by Pfizer of PF-08046052,” CEO Stephen Hurly remarked.

PM Images LAVA Therapeutics（纳斯达克：LVTX）周二宣布，辉瑞（Pfizer）在其癌症候选人PF-08046052的临床计划中达到了一个关键的里程碑，导致向荷兰生物技术公司支付700万美元，这是两家公司合作的第一笔里程碑付款。首席执行官斯蒂芬·赫尔利（StephenHurly）表示：“我们非常高兴辉瑞公司开始临床开发PF-08046052。”。

“The initiation of the Phase 1 study for PF-08046052 marks the third asset utilizing LAVA’s Gammabody platform to enter the clinic,” he added. PF-08046052 is currently undergoing a Phase 1 trial as part of a licensing deal Pfizer (PFE) unit Seagen and LAVA reached in September 2022. According to its terms, LVTX was eligible for $50M upfront and up to ~$650M in milestone payments and royalties on potential sales.

他补充道：“PF-08046052的第一阶段研究的启动标志着利用LAVA的Gammabody平台进入诊所的第三项资产。”。PF-08046052目前正在进行第一阶段试验，作为2022年9月达成的辉瑞（PFE）旗下Seagen and LAVA许可协议的一部分。根据其条款，LVTX有资格获得5000万美元的预付款，以及高达约6.5亿美元的里程碑付款和潜在销售的版税。

More on LAVA Therapeutics LAVA stock rises on clinical trial collaboration with Merck Seeking Alpha’s Quant Rating on LAVA Therapeutics Historical earnings data for LAVA Therapeutics Financial information for LAVA Therapeutics .

更多关于LAVA Therapeutics的信息LAVA股票在临床试验中与默克公司合作，寻求Alpha对LAVA Therapeutics的定量评级LAVA Therapeutics的历史收益数据LAVA Therapeutics的财务信息。